BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson's Disease. Front Neurosci 2019;13:992. [PMID: 31611762 DOI: 10.3389/fnins.2019.00992] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Klæstrup IH, Just MK, Holm KL, Alstrup AKO, Romero-ramos M, Borghammer P, Van Den Berge N. Impact of aging on animal models of Parkinson's disease. Front Aging Neurosci 2022;14:909273. [DOI: 10.3389/fnagi.2022.909273] [Reference Citation Analysis]
2 Terenzi D, Muth A, Park SQ. Nutrition and Gut–Brain Pathways Impacting the Onset of Parkinson’s Disease. Nutrients 2022;14:2781. [DOI: 10.3390/nu14142781] [Reference Citation Analysis]
3 Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, Chen F, Ling Z. Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease. Front Immunol 2022;13:937555. [DOI: 10.3389/fimmu.2022.937555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jackson A, Engen PA, Forsyth CB, Shaikh M, Naqib A, Wilber S, Frausto DM, Raeisi S, Green SJ, Bradaric BD, Persons AL, Voigt RM, Keshavarzian A. Intestinal Barrier Dysfunction in the Absence of Systemic Inflammation Fails to Exacerbate Motor Dysfunction and Brain Pathology in a Mouse Model of Parkinson's Disease. Front Neurol 2022;13:882628. [DOI: 10.3389/fneur.2022.882628] [Reference Citation Analysis]
5 Pavan S, Prabhu AN, Prasad Gorthi S, Das B, Mutreja A, Shetty V, Ramamurthy T, Ballal M. Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease. Folia Microbiol (Praha) 2022. [PMID: 35583791 DOI: 10.1007/s12223-022-00977-2] [Reference Citation Analysis]
6 Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 2022. [PMID: 35246670 DOI: 10.1038/s41577-022-00684-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
7 Rusch C, Beke M, Tucciarone L, Nieves C Jr, Ukhanova M, Tagliamonte MS, Mai V, Suh JH, Wang Y, Chiu S, Patel B, Ramirez-Zamora A, Langkamp-Henken B. Mediterranean Diet Adherence in People With Parkinson's Disease Reduces Constipation Symptoms and Changes Fecal Microbiota After a 5-Week Single-Arm Pilot Study. Front Neurol 2021;12:794640. [PMID: 35002935 DOI: 10.3389/fneur.2021.794640] [Reference Citation Analysis]
8 Piri H, Sharifi S, Nigjeh S, Haghdoost-Yazdi H. Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-α and IL-1β; evidence from early experimental model of Parkinson's disease. Neurol Res 2022;:1-10. [PMID: 34986749 DOI: 10.1080/01616412.2021.2024726] [Reference Citation Analysis]
9 Ghyselinck J, Verstrepen L, Moens F, Van Den Abbeele P, Bruggeman A, Said J, Smith B, Barker LA, Jordan C, Leta V, Chaudhuri KR, Basit AW, Gaisford S. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease. Int J Pharm X 2021;3:100087. [PMID: 34977556 DOI: 10.1016/j.ijpx.2021.100087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Koszewicz M, Mulak A, Dziadkowiak E, Budrewicz S. Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? - A Pilot Study. Front Hum Neurosci 2021;15:733070. [PMID: 34867240 DOI: 10.3389/fnhum.2021.733070] [Reference Citation Analysis]
11 Becker A, Pierre Schmartz G, Gröger L, Grammes N, Galata V, Philippeit H, Weiland J, Ludwig N, Meese E, Tierling S, Walter J, Schwiertz A, Spiegel J, Wagenpfeil G, Faßbender K, Keller A, Unger MM. Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson's Disease - the RESISTA-PD Trial. Genomics Proteomics Bioinformatics 2021:S1672-0229(21)00245-X. [PMID: 34839011 DOI: 10.1016/j.gpb.2021.08.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
12 Kowalski K, Mulak A. Small intestinal bacterial overgrowth in Alzheimer's disease. J Neural Transm (Vienna) 2021. [PMID: 34797427 DOI: 10.1007/s00702-021-02440-x] [Reference Citation Analysis]
13 Dănău A, Dumitrescu L, Lefter A, Tulbă D, Popescu BO. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease. Int J Mol Sci 2021;22:11663. [PMID: 34769091 DOI: 10.3390/ijms222111663] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Behringer V, Müller-Klein N, Strube C, Schülke O, Heistermann M, Ostner J. Responsiveness of fecal immunoglobulin A to HPA-axis activation limits its use for mucosal immunity assessment. Am J Primatol 2021;83:e23329. [PMID: 34554596 DOI: 10.1002/ajp.23329] [Reference Citation Analysis]
15 Rusch C, Beke M, Tucciarone L, Dixon K, Nieves C Jr, Mai V, Stiep T, Tholanikunnel T, Ramirez-Zamora A, Hess CW, Langkamp-Henken B. Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease (the MEDI-PD study): study protocol for a randomised controlled trial. BMJ Open 2021;11:e053336. [PMID: 34551955 DOI: 10.1136/bmjopen-2021-053336] [Reference Citation Analysis]
16 Houser MC, Caudle WM, Chang J, Kannarkat GT, Yang Y, Kelly SD, Oliver D, Joers V, Shannon KM, Keshavarzian A, Tansey MG. Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. Acta Neuropathol Commun 2021;9:139. [PMID: 34412704 DOI: 10.1186/s40478-021-01240-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
17 Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A. Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. Mol Neurobiol 2021. [PMID: 34350555 DOI: 10.1007/s12035-021-02500-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Dumitrescu L, Marta D, Dănău A, Lefter A, Tulbă D, Cozma L, Manole E, Gherghiceanu M, Ceafalan LC, Popescu BO. Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease. Front Neurosci 2021;15:689723. [PMID: 34220443 DOI: 10.3389/fnins.2021.689723] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
19 Muntjewerff EM, Tang K, Lutter L, Christoffersson G, Nicolasen MJT, Gao H, Katkar GD, Das S, Ter Beest M, Ying W, Ghosh P, El Aidy S, Oldenburg B, van den Bogaart G, Mahata SK. Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides. Acta Physiol (Oxf) 2021;232:e13655. [PMID: 33783968 DOI: 10.1111/apha.13655] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
20 Vojdani A, Lerner A, Vojdani E. Cross-Reactivity and Sequence Homology Between Alpha-Synuclein and Food Products: A Step Further for Parkinson's Disease Synucleinopathy. Cells 2021;10:1111. [PMID: 34063062 DOI: 10.3390/cells10051111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
21 Lerner A. The intestinal luminal sources of α-synuclein: a gastroenterologist perspective. Nutr Rev 2021:nuab024. [PMID: 33942062 DOI: 10.1093/nutrit/nuab024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Becker A, Abuazab M, Schwiertz A, Walter S, Faßbender KC, Fousse M, Unger MM. Short-chain fatty acids and intestinal inflammation in multiple sclerosis: modulation of female susceptibility by microbial products? Auto Immun Highlights 2021;12:7. [PMID: 33827656 DOI: 10.1186/s13317-021-00149-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG, Scheperjans F. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease. Mol Neurodegener 2021;16:6. [PMID: 33557896 DOI: 10.1186/s13024-021-00427-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
24 Cossais F, Schaeffer E, Heinzel S, Zimmermann J, Niesler B, Röth R, Rappold G, Scharf A, Zorenkov D, Lange C, Barrenschee M, Margraf NG, Ellrichmann M, Berg D, Böttner M, Wedel T. Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson's Disease Patients. J Parkinsons Dis 2021;11:171-6. [PMID: 33337386 DOI: 10.3233/JPD-202258] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Gorecki AM, Bakeberg MC, Theunissen F, Kenna JE, Hoes ME, Pfaff AL, Akkari PA, Dunlop SA, Kõks S, Mastaglia FL, Anderton RS. Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease. Front Aging Neurosci 2020;12:603849. [PMID: 33328979 DOI: 10.3389/fnagi.2020.603849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
26 Unger MM, Becker A, Keller A, Schäfer KH, Schwiertz A, Oertel WH. [The role of the gut microbiome in idiopathic Parkinson's disease]. Nervenarzt 2020;91:1085-95. [PMID: 33025073 DOI: 10.1007/s00115-020-01011-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Pajares M, I Rojo A, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications. Cells 2020;9:E1687. [PMID: 32674367 DOI: 10.3390/cells9071687] [Cited by in Crossref: 121] [Cited by in F6Publishing: 88] [Article Influence: 60.5] [Reference Citation Analysis]
28 Wallings RL, Herrick MK, Tansey MG. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. Front Neurosci 2020;14:443. [PMID: 32508566 DOI: 10.3389/fnins.2020.00443] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
29 Hegelmaier T, Lebbing M, Duscha A, Tomaske L, Tönges L, Holm JB, Bjørn Nielsen H, Gatermann SG, Przuntek H, Haghikia A. Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson's Disease. Cells 2020;9:E376. [PMID: 32041265 DOI: 10.3390/cells9020376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]